Factors affecting tyrosine kinase inhibitors response in chronic myeloid leukemia patients
Not Applicable
Active, not recruiting
- Conditions
- Despite the excellent efficacy obtained for the treatment of CML,a significant proportion of patients develop resistance to tyrosine kinase inhibitors.
- Registration Number
- TCTR20180703001
- Lead Sponsor
- /A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
•Thai patients with chronic myeloid leukemia received tyrosine kinase inhibitors for at least 6 months in Srinagarind Hospital.
•The patients are at least 18 years of age.
•The patients are willing to participate in the study and signed a consent form.
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Drug response Within 3 months after the patients took tyrosine kinase inhibitors Lab results
- Secondary Outcome Measures
Name Time Method Adverse drug reactions Within 3 months after the patients took tyrosine kinase inhibitors Medical record review, interview